CG Oncology, Inc.
CGON
$17.20
-$1.54-8.22%
| Weiss Ratings | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -36.15% | |||
| 30-Day Total Return | -35.77% | |||
| 60-Day Total Return | -43.53% | |||
| 90-Day Total Return | -48.61% | |||
| Year to Date Total Return | -40.63% | |||
| 1-Year Total Return | -55.28% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -63.40% | |||
| 52-Week Low % Change | 3.40% | |||
| Price | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $46.99 | |||
| 52-Week Low Price | $16.64 | |||
| 52-Week Low Price (Date) | Apr 04, 2025 | |||
| 52-Week High Price (Date) | May 03, 2024 | |||
| Valuation | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.31B | |||
| Enterprise Value | 569.17M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.41 | |||
| Earnings Per Share Growth | -87.83% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1,048.78 | |||
| Price/Book (Q) | 1.79 | |||
| Enterprise Value/Revenue (TTM) | 499.71 | |||
| Price | $17.20 | |||
| Enterprise Value/EBITDA (TTM) | -4.97 | |||
| Enterprise Value/EBIT | -4.96 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 69.05M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 409 3700 | |||
| Address | 400 Spectrum Center Drive Irvine, CA 92618 | |||
| Website | cgoncology.com | |||
| Country | United States | |||
| Year Founded | 2010 | |||
| Profitability | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -10,067.25% | |||
| Profit Margin | -7,729.32% | |||
| Management Effectiveness | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.02% | |||
| Return on Equity | -- | |||
| Income Statement | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.14M | |||
| Total Revenue (TTM) | 1.14M | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | -80.96M | |||
| EBITDA (TTM) | -114.63M | |||
| EBIT (TTM) | -114.67M | |||
| Net Income (TTM) | -88.04M | |||
| Net Income Avl. to Common (TTM) | -88.04M | |||
| Total Revenue Growth (Q YOY) | 45,500.00% | |||
| Earnings Growth (Q YOY) | -92.07% | |||
| EPS Diluted (TTM) | -1.41 | |||
| EPS Diluted Growth (Q YOY) | 89.43% | |||
| Balance Sheet | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 742.00M | |||
| Cash Per Share (Q) | $10.75 | |||
| Total Current Assets (Q) | 754.21M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 733.38M | |||
| Current Ratio (Q) | 35.296 | |||
| Book Value Per Share (Q) | $9.63 | |||
| Total Assets (Q) | 754.80M | |||
| Total Current Liabilities (Q) | 21.37M | |||
| Total Debt (Q) | 238.00K | |||
| Total Liabilities (Q) | 21.42M | |||
| Total Common Equity (Q) | 733.38M | |||
| Cash Flow | CGON - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -300.76M | |||
| Cash from Financing (TTM) | 628.28M | |||
| Net Change in Cash (TTM) | 248.80M | |||
| Levered Free Cash Flow (TTM) | -59.08M | |||
| Cash from Operations (TTM) | -78.71M | |||
